20/20 Biolabs, Inc. · NASDAQ:AIDX
20/20 Biolabs — Investor Presentation (July 2026)
16 slides from 20/20 Biolabs's investor presentation, Jul 1, 2026
Slide 1: Investor Webinar July 1, 2026
NASDAQ: AIDX Investor Webinar July 1, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information c
Slide 3: Congress Creates a Pathway for Medicare Reimbursement for Multi-Cancer Tests by 2028
Congress Creates a Pathway for Medicare Reimbursement for Multi- Cancer Tests by 2028 • Establishes the first statutory pathway for Medicare coverage of MCED blood tests • CMS authority to reimburse MCEDs beginning in 2028 • Applies to FDA-approved MCED tests deemed clinically appropriate by CMS • I
Slide 4: Grail's NHS-Galleri Data at ASCO Signals Trouble for Medicare Coverage of Galleri
Grail's NHS-Galleri Data at ASCO Signals Trouble for Medicare Coverage of Galleri • Primary endpoint missed — no drop in combined Stage III/IV cancers overall • Stage I–II diagnoses rose just 16% when added to standard screening — unlikely to translate into a meaningful mortality benefit • ctDNA mis
Slide 5: OneTest for Medicare: Biomarker Tracking + Machine Learning + Anti-Inflammatory Diet
OneTest for Medicare: Biomarker Tracking + Machine Learning + Anti-Inflammatory Diet Biomarker Panel: 12 Markers Cancer protein tumor markers (PTMs) • AFP — liver, testicular, ovarian • CEA — lung, pancreatic, GI • CA 19-9 — pancreatic, liver, GI • CA 125 — ovarian, lung • CYFRA 21-1 — lung, head/ne
Slide 6: OneTest for Medicare: The first MCED aligned with CMS' MAHA ELEVATE Nutritional Mandate
OneTest for Medicare: Biomarker Tracking + Machine Learning + Anti-Inflammatory Diet The first MCED aligned w/ CMS' MAHA ELEVATE Nutritional Mandate Score the diet: DII + FFQ • A Food Frequency Questionnaire (FFQ) converts habitual intake into a Dietary Inflammatory Index (DII): negative is anti- in
Slide 7: OneTest Advantages Over ctDNA — Our "Straight A's"
OneTest Advantages Over ctDNA — Our "Straight A's" • Accuracy for Earlier Stage Cancers • Affordability • Acceleration over Time • Aggregates Data from Multiple Sources • Access at Home & Workplaces • AI Compatible for Consumers & Clinicians
Slide 8: Types of Evidence Supporting FDA Authorization & CMS Coverage
Types of Evidence Supporting FDA Authorization & CMS Coverage A totality-of-evidence package, not randomized trials: We intend to support FDA De Novo or PMA authorization and CMS coverage through a totality-of-evidence approach incorporating analytical validity, clinical validity, and real-world evi
Slide 9: Testing U.S. Firefighters also Provides Real-World Data
Testing U.S. Firefighters also Provides Real-World Data • Over 35,000 American firefighters will have been tested by the end of 2026 • Nearly 35% of Fire Departments reorder yearly • CDC's National Firefighter Cancer Registry may provide "one-stop shopping" for reliable outcome data enabling the sam
Slide 10: OneTest for Medicare: Modeled Earlier Stage Sensitivity & Specificity by Testing Frequency
10 OneTest for Medicare: Modeled Earlier Stage Sensitivity & Specificity by Testing Frequency Cancer (early-stage sensitivity) Test Once (1 test) Yearly × 3 yrs (3 tests) 2× / yr × 3 yrs (6 tests) Quarterly × 3 yrs (12 tests) Liver 55% 75% 84% 88% Lung 40% 58% 68% 73% Colorectal 45% 63% 72% 77% Panc
Slide 11: At Home Capillary Collection Now Makes Quarterly Testing Practical & Velocity Algorithms Impactful
11 At Home Capillary Collection Now Makes Quarterly Testing Practical & Velocity Algorithms Impactful
Slide 12: OneTest for Longevity Makes It Easy to Stay on Top of Overall Health
OneTest for Longevity Makes It Easy to Stay on Top of Overall Health Biomarker Trends Individual inflammatory biomarker levels, including trends from previous tests through our lab. Personalized Analysis Comprehensive science-based diet and lifestyle analysis to help you achieve your longevity goals
Slide 13: M&A Strategy: Bolt-on or Acquire Complementary Companies
13 Expect to "bolt-on" or acquire other companies that are vertically or horizontally integrated with 20/20 (e.g., suppliers, distributors, or related products) M&A Strategy Desired Attributes for Acquired Companies • Health & wellness customer base overlaps with those of 20/20 - Early Cancer Detect
Slide 14: How Cologuard's 2014 Medicare Coverage Ignited Exponential Revenue Growth
14 How Cologuard's 2014 Medicare Coverage Ignited Exponential Revenue Growth 4 4 2 39 99 266 0 50 100 150 200 250 300 2012 2013 2014 2015 2016 2017 Annual Revenue ($M) ← Medicare Coverage October 2014 FDA Approval Aug 11, 2014 — First stool DNA test approved Medicare NCD Issued Oct 9, 2014 — Coverag
Slide 15: Revenue Projections & Royalty Pool Sharing Following Medicare Reimbursement
Revenue Projections & Royalty Pool Sharing Following Medicare Reimbursement Based on 20% Premium over Exact Sciences (Cologuard) Five percent royalty pool on revenues over first 5 years ~ $100 million Royalty pool to be shared with "data investors" on a pro-rata basis Revenue projections (in $millio
Slide 16: Key Takeaway: Upside of a Biopharma with Downside Protection of a Dx Company
Key Takeaway: AIDX has the upside potential of a biopharmaceutical company (in Phase II clinical trials) with the downside protection of an early revenue stage Dx or medtech company Jonathan Cohen CEO 240-453-6343 Investors@2020Biolabs.com NASDAQ: AIDX 2020biolabs.com